Cell and Gene Therapy Trials Supported by Gates Institute

Studies which are currently taking place and are enrolling new participants:

Phase I/II Dose Escalation and Preliminary Efficacy of CD19-Directed CAR-T Cells (UCD19) in Pediatric Patients with Relapsed/Refractory B-ALL and B-NHL

Trial #: 18-2424                                  NCT ID: NCT04544592
Disease Area: Leukemia (ALL)          Site: Children’s Hospital Colorado
Principal Investigator: Vanessa Fabrizio, MD

Phase 1/1b Safety & Tolerability of CD19-Directed CAR-T in Adult B-ALL with MRD Positivity at First CR

Trial #: 22-0054                                  NCT ID: NCT05535855
Disease Area: Leukemia (ALL)          Site: UCHealth University of Colorado Hospital
Principal Investigator: Marc Schwartz, MD

Phase I Dose Escalation & Preliminary Efficacy of Bispecific CD19x22 CAR-T in Pediatric R/R B-ALL

Trial #: 22-0998                                  NCT ID: NCT06559189
Disease Area: Leukemia (ALL)          Site: Children’s Hospital Colorado
Principal Investigator: Vanessa Fabrizio, MD

Phase 1/1b Study of Bispecific CD19x22 CAR-T in Adolescent & Adult Patients with R/R B-NHL

Trial #: 21-2578                                  NCT ID: NCT05098613
Disease Area: Lymphoma (B-cell)     Site: UCHealth University of Colorado Hospital
Principal Investigator: Manali Kamdar, MD